Anaptysbio (ANAB) Operating Leases (2021 - 2026)

Anaptysbio's Operating Leases history runs 6 years deep, the most recent figure standing at $11.5 million for Q1 2026.

• Quarterly Operating Leases fell 15.57% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 15.57% YoY) and the FY2025 annual result came in at $12.0 million, down 14.74% from the prior year.
• Operating Leases was $11.5 million for Q1 2026 at Anaptysbio, down from $12.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $20.2 million in Q2 2022 and bottomed at $11.5 million in Q1 2026.
• A 5-year average of $15.8 million and a median of $16.0 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases retreated 2.67% — and 2025, when it decreased 22.73%.
• Anaptysbio's Operating Leases stood at $17.8 million in 2022, then slipped by 9.97% to $16.0 million in 2023, then slipped by 12.0% to $14.1 million in 2024, then dropped by 14.74% to $12.0 million in 2025, then retreated by 4.48% to $11.5 million in 2026.
• Business Quant data shows ANAB's Operating Leases at $11.5 million in Q1 2026, $12.0 million in Q4 2025, and $12.6 million in Q3 2025.